Loading…
Aquestive Therapeutics, Inc. is projected to rise to $4.23 by 2027, a +14% move from its current price of $3.70. AQST is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $3.60 | $3.70 | $3.79 | +0.01% |
| Aug 4 | $3.56 | $3.70 | $3.83 | +0.02% |
| Aug 5 | $3.53 | $3.70 | $3.87 | +0.02% |
| Aug 6 | $3.51 | $3.70 | $3.89 | +0.03% |
| Aug 7 | $3.49 | $3.70 | $3.92 | +0.04% |
| Aug 8 | $3.47 | $3.70 | $3.94 | +0.05% |
| Aug 9 | $3.45 | $3.70 | $3.96 | +0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.45 | $3.70 | $3.96 | +0.05% |
| Week 2 | $3.36 | $3.70 | $4.08 | +0.11% |
| Week 3 | $3.28 | $3.70 | $4.17 | +0.16% |
| Week 4 | $3.23 | $3.70 | $4.25 | +0.21% |
| Week 5 | $3.18 | $3.70 | $4.32 | +0.27% |
| Week 6 | $3.13 | $3.71 | $4.39 | +0.32% |
| Week 7 | $3.09 | $3.71 | $4.45 | +0.37% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older.
The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
AQST is the stock of Aquestive Therapeutics, Inc. It is currently priced at $3.77 per share, with a market capitalization of $473.01M and a market rank of 3019. The price outlook reflected in the year-by-year forecast shows a near-term stability around the current level with a path to higher prices over the longer term.
A major floor 27.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.6% away) — a key level to hold.
The nearest ceiling, 36.1% above — a clean break opens room to run.
A major ceiling 49.9% above — clearing it would confirm fresh momentum.
Key AQST support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AQST market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.70 | Sell | $3.71 | Sell |
| MA 10 | $3.79 | Sell | $3.79 | Sell |
| MA 20 | $3.96 | Sell | $3.92 | Sell |
| MA 50 | $4.12 | Sell | $4.07 | Sell |
| MA 100 | $4.14 | Sell | $4.19 | Sell |
| MA 200 | $4.70 | Sell | $4.30 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.92 | Neutral |
| Stoch RSI (14) | 37.93 | Neutral |
| CCI (20) | -96.22 | Neutral |
| Williams %R (14) | -81.73 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -6.46 | Sell |
| Bollinger %B (20,2) | 0.20 | Neutral |
| Stochastic %K (14) | 18.27 | Buy |
| TRIX (15) | -0.42 | Sell |
| Awesome (5,34) | -0.46 | Sell |
| Ultimate (7,14,28) | 32.79 | Neutral |
| Momentum (10) | -0.42 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 3.65 | Buy |
| ADX (14) | 18.33 | Neutral |
| ATR (14) | 0.10 | Info |
The 14-day momentum is neutral, with RSI14 at 40. The 50-day simple moving average (SMA50) is $4.19 and the 200-day simple moving average (SMA200) is $4.78. The price currently sits at support of $3.77 and faces resistance at $5.03. The 30-day price range spans from $3.13 to $4.53.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.95 | $3.70 | $4.95 | 0% | Neutral | |
| $3.38 | $4.23 | $5.57 | +14% | Neutral | |
| $3.70 | $4.74 | $6.48 | +28% | Bullish | |
| $3.66 | $4.80 | $6.75 | +30% | Bullish | |
| $3.83 | $5.12 | $7.36 | +38% | Bullish | |
| $4.63 | $6.30 | $9.25 | +70% | Bullish | |
| $5.32 | $7.36 | $11.02 | +99% | Bullish | |
| $5.71 | $8.03 | $12.21 | +117% | Bullish | |
| $5.91 | $8.42 | $13.01 | +128% | Bullish | |
| $6.15 | $8.90 | $13.94 | +141% | Bullish | |
| $9.02 | $13.89 | $23.10 | +276% | Bullish | |
| $13.95 | $23.93 | $43.44 | +548% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.95 | $3.70 | $4.55 | +0.00% |
| September 2026 | $3.19 | $3.77 | $4.57 | +1.91% |
| October 2026 | $3.13 | $3.72 | $4.56 | -1.20% |
| November 2026 | $3.22 | $3.84 | $4.75 | +3.33% |
| December 2026 | $3.31 | $3.97 | $4.95 | +3.33% |
Click any year to see its month-by-month AQST forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The AQST price prediction for 2026 points to an average of $3.70 (low $2.95, high $4.95) — a potential gain of 0% on today's $3.70. Price action looks broadly range-bound.
In 2027, AQST is projected to trade between $3.38 and $5.57, averaging $4.23 — a potential gain of +14% from today's $3.70. That is up +14% on the projected 2026 average. A consolidation phase looks the most probable path here.
Aquestive Therapeutics, Inc.'s 2028 outlook centres on $4.74, within a $3.70 to $6.48 range. That is up +12% on the projected 2027 average. That marks a +28% change versus current levels. Momentum favours further upside here.
By 2029, AQST could reach as high as $6.75, with a base case around $4.80 and support toward $3.66 — roughly +30% from $3.70. Buyers look set to stay in control over this stretch.
Expect AQST to range from $3.83 to $7.36 through 2030. The $5.12 average target implies a +38% move from current prices. That is up +6% on the projected 2029 average. Momentum favours further upside here.
The AQST price prediction for 2031 points to an average of $6.30 (low $4.63, high $9.25) — a potential gain of +70% on today's $3.70. Buyers look set to stay in control over this stretch.
In 2032, AQST is projected to trade between $5.32 and $11.02, averaging $7.36 — a potential gain of +99% from today's $3.70. That is up +17% on the projected 2031 average. Momentum favours further upside here.
Aquestive Therapeutics, Inc.'s 2033 outlook centres on $8.03, within a $5.71 to $12.21 range. That is up +9% on the projected 2032 average. That marks a +117% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, AQST could reach as high as $13.01, with a base case around $8.42 and support toward $5.91 — roughly +128% from $3.70. Momentum favours further upside here.
Expect AQST to range from $6.15 to $13.94 through 2035. The $8.90 average target implies a +141% move from current prices. That is up +6% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The AQST price prediction for 2040 points to an average of $13.89 (low $9.02, high $23.10) — a potential gain of +276% on today's $3.70. Momentum favours further upside here.
In 2050, AQST is projected to trade between $13.95 and $43.44, averaging $23.93 — a potential gain of +548% from today's $3.70. That is up +72% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in AQST today (≈ 270.635995 AQST) could be worth
$6,475.98
+$5,475.98 (+548%) by 2050 · US Dollar
Based on the average projected AQST price of $23.93 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AQSTwould be worth at today's price.
$1,000 invested in AQST on Jul 31, 2025 (≈ 260.416672 AQST) would be worth
$962.24
-$37.76 (-3.8%) today · 0.96× · US Dollar
Based on a AQST entry price of $3.84 vs. today's $3.7.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.68 | $1,004.08 | +0.4% |
| 1 month ago | $4.24 | $871.46 | -12.9% |
| 3 months ago | $4.2 | $879.76 | -12.0% |
| 6 months ago | $4.1 | $901.22 | -9.9% |
| 1 year ago | $3.84 | $962.24 | -3.8% |
| All time (5.0y) ago | $3.25 | $1,136.92 | +13.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AQST forecast.
Our base-case forecast reaches $7.40 around 2033.
Implied market cap at $7.40: $928.46M
The multi-year forecast points to a bullish trajectory after 2026. For 2026 the average price is $3.77 with a min $2.95 and max $5.11 (ROI 0; sentiment NEUTRAL). In 2027 the average climbs to $4.33 (min $3.44, max $5.76; ROI 14.9; sentiment NEUTRAL).
The series continues with 2028 at $4.94 (min $3.81, max $6.83; ROI 30.9; sentiment BULLISH) and 2029 at $4.94 (min $3.72, max $7.04; ROI 31; sentiment BULLISH). By 2030 the average is $5.30 (min $3.91, max $7.74; ROI 40.6; sentiment BULLISH). The forecast then extends through 2031–2035 with steady gains, culminating in 2031 avg $6.75, 2032 avg $7.79, 2033 avg $8.50, 2034 avg $9.07, and 2035 avg $9.42, all labeled BULLISH.
In 2040 the average price is projected at $15.13 (min $9.57, max $25.76; ROI 301.3; sentiment BULLISH), and in 2050 the average reaches $25.90 (min $14.54, max $48.32; ROI 587; sentiment BULLISH). These are estimates and not guarantees.
Tap a question to reveal the answer.
The forecast for 2030 shows min $3.91, avg $5.30, max $7.74 and a forecast ROI of 40.6, with a BULLISH sentiment.
Forecasts indicate a progression from NEUTRAL in 2026 to BULLISH later years, with 2026 avg $3.77 and 2050 avg $25.90, and ROI reaching 587 in 2050.
The maximum forecast in the data is $48.32 by 2050, so a price of $100 is not indicated.
The current price is $3.77 and the market capitalization is $473.01M.
The 30-day range is $3.13 to $4.53.
Aquestive Therapeutics, Inc. Community Discussion
0Share your Aquestive Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.